GeneCentric Therapeutics Enters Bladder Cancer Research Collaboration with University of North Carol ...
LEARN MORE
GeneCentric's Cancer Subtyping Platform (CSP®)
Our initial approach to developing universal drug response biomarkers is based on the CSP® technology we developed for generating high resolution, genomic-defined cancer subtypes.
These unique genomic profiles are designed to characterize tumor biology in a manner that enables optimal targeting of therapeutic compounds. The CSP profilers combine gene expression data with disease-related molecular pathways and immune cell expression to identify therapy response signatures using advanced computational biology technologies.
LEARN MOREOur Growing Portfolio of Cancer Profilers
GeneCentric is building a pipeline of universal cancer subtypes/biomarkers for the most prevalent and complex cancers. Profilers are currently available in the areas of lung cancer – the leading cause of cancer deaths in the U.S. – and head and neck cancer.
LEARN MORE
Achieving Greater Progress Through Effective Collaboration
GeneCentric is proud to collaborate with some of the world’s leading research and development organizations. By bringing together our unique strengths and proprietary technology with that of our partners we are able to rapidly and efficiently translate the most promising science and advance drug development, delivering new hope to those fighting cancer today.
LEARN MOREGeneCentric Adds Unique Value at Every Stage of Drug Development
Development Stage Involvement
Drive translational research to FIM through novel in-silico and in-vivo modeling
Enable clear segmentation of patients via subtyping during early drug development
Confirm subtype profilers as response biomarkers supporting accelerated drug, and companion diagnostic, development
Expand subtypes drug-response biomarkers in confirmatory and indication expansion studies to maximize market potential
Reposition and repurpose drugs by subtyping patients to reveal new or additional drug responder populations and commercial potential
Making News: Our Latest Progress, Partnerships and Impact
December 10, 2018
September 24, 2018
GeneCentric Therapeutics Licenses Pancreatic Cancer Subtyping Technology from University of North Ca ...
LEARN MORE
September 10, 2018
GeneCentric Therapeutics Appoints Michael V. Milburn, PhD, Chief Scientific Officer
LEARN MORE